On Mar. 24, 2020, Dynavax Technologies and Clover Biopharmaceuticals, a China-based global clinical-stage biotechnology company, announceda research collaboration to develop a vaccine candidate to prevent COVID-19. Clover is advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) in preclinical studies. Dynavax is providing technical expertise and the companyﾒs proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.